### Appendix 8: Data Extraction

**Appendix 8 Table 1: Data Extraction Table (example based on Vaccine Preventive Disease)**

<table>
<thead>
<tr>
<th>Included Studies</th>
<th>Summary of Findings Table</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Author</strong></td>
<td><strong>Year</strong></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Appendix 8, Table 2: Quality Assessment of Included Reviews using the AMSTAR Tool (example)

<table>
<thead>
<tr>
<th>Author</th>
<th>Title</th>
<th>SIGN 50/ AMSTAR Score</th>
</tr>
</thead>
<tbody>
<tr>
<td>Zhang 2014</td>
<td>Acellular vaccines for preventing whooping cough in children.</td>
<td>9 out of 11</td>
</tr>
</tbody>
</table>
Appendix 8, Table 3: Quality of Evidence for Outcomes

<table>
<thead>
<tr>
<th>Included Studies</th>
<th>Quality of Evidence for Outcomes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Author</td>
<td>Risk of Bias</td>
</tr>
<tr>
<td>Zhang (2014) Acellular vaccines for preventing whooping cough in children</td>
<td></td>
</tr>
<tr>
<td>Outcomes</td>
<td></td>
</tr>
<tr>
<td>1. Noncompletion due to adverse events: acellular versus whole cell pertussis</td>
<td>Serious (1)</td>
</tr>
</tbody>
</table>
## Appendix 8, Table 4. Selected outcomes

<table>
<thead>
<tr>
<th><strong>Tuberculosis</strong></th>
<th>Importance</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hepatotoxicity</td>
<td>Critical</td>
</tr>
<tr>
<td>Active TB follow-up</td>
<td>Critical</td>
</tr>
<tr>
<td>Drug-resistant TB</td>
<td>Critical</td>
</tr>
<tr>
<td>Treatment limiting adverse events</td>
<td>Important</td>
</tr>
<tr>
<td>Haematological adverse events</td>
<td>Important</td>
</tr>
</tbody>
</table>

### Hepatitis B

<table>
<thead>
<tr>
<th>Hepatitis B</th>
<th>Importance</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hepatocellular carcinoma</td>
<td>Critical</td>
</tr>
<tr>
<td>HCC mortality</td>
<td>Critical</td>
</tr>
<tr>
<td>HBeAg loss</td>
<td>Important</td>
</tr>
<tr>
<td>HBV DNA loss</td>
<td>Important</td>
</tr>
<tr>
<td>HBsAg loss</td>
<td>Important</td>
</tr>
<tr>
<td>Histologic improvement</td>
<td>Important</td>
</tr>
<tr>
<td>HBsAg carriage</td>
<td>Important</td>
</tr>
<tr>
<td>Liver cancers (except non-hepatocellular carcinoma)</td>
<td>Important</td>
</tr>
</tbody>
</table>

### Hepatitis C

<table>
<thead>
<tr>
<th>Hepatitis C</th>
<th>Importance</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mortality due to HCV</td>
<td>Critical</td>
</tr>
<tr>
<td>Hepatocellular Carcinoma</td>
<td>Critical</td>
</tr>
<tr>
<td>Hospitalizations due to HCV</td>
<td>Important</td>
</tr>
<tr>
<td>Quality of life</td>
<td>Important</td>
</tr>
<tr>
<td>Sustained virological response rates (SVR), histological improvements due to treatment</td>
<td>Important</td>
</tr>
<tr>
<td>Reduced HCV transmission</td>
<td>Important</td>
</tr>
<tr>
<td>Harms of screening due to over diagnosis/overtreatment</td>
<td>Important</td>
</tr>
</tbody>
</table>

### Measles, mumps, rubella, polio and tetanus, diphtheria, pertussis, haemophilus influenzae type B

<table>
<thead>
<tr>
<th>Measles, mumps, rubella, polio and tetanus, diphtheria, pertussis, haemophilus influenzae type B</th>
<th>Importance</th>
</tr>
</thead>
<tbody>
<tr>
<td>Morbidity</td>
<td>Critical</td>
</tr>
<tr>
<td>Mortality</td>
<td>Critical</td>
</tr>
<tr>
<td>Vaccine efficacy</td>
<td>Important</td>
</tr>
<tr>
<td>Non-completion due to adverse events</td>
<td>Important</td>
</tr>
</tbody>
</table>
### Intestinal parasites

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Overall cure</td>
<td>Critical</td>
</tr>
<tr>
<td>Mortality due to schistosomiasis</td>
<td>Critical</td>
</tr>
<tr>
<td>Risk of severe strongyloidiasis in immunosuppressed patients</td>
<td>Important</td>
</tr>
<tr>
<td>% egg reduction</td>
<td>Important</td>
</tr>
<tr>
<td>Micro haematuria</td>
<td>Important</td>
</tr>
<tr>
<td>Haemoglobin</td>
<td>Important</td>
</tr>
</tbody>
</table>